# Correction: LC-MS/MS characterization of pirtobrutinib impurities and product degradation: stability studies

**Authors:** Modachakanahally K. Pavithra, Chaya G., Hemavathi N. Deepakumari, Hosakere D. Revanasiddappa, Salah Jasim Mohammed, Hasan Sh. Majdi, Abdullah H. Alsabhan, Shareefraza J. Ukkund

PMC · DOI: 10.1039/d5ra90116b · RSC Advances · 2025-10-20

## TL;DR

This paper corrects a previously published study on the characterization of pirtobrutinib impurities and degradation products using LC-MS/MS.

## Contribution

The paper provides a correction to prior findings, ensuring accuracy in the characterization of pirtobrutinib impurities and degradation.

## Key findings

- The correction addresses errors in the original study's characterization of pirtobrutinib impurities.
- Updated data ensures more reliable stability and degradation analysis of pirtobrutinib.

## Abstract

Correction for ‘LC-MS/MS characterization of pirtobrutinib impurities and product degradation: stability studies’ by Modachakanahally K. Pavithra et al., RSC Adv., 2024, 14, 34868–34882, https://doi.org/10.1039/D4RA06299J.

## Linked entities

- **Chemicals:** pirtobrutinib (PubChem CID 129269915)

## Full-text entities

- **Chemicals:** pirtobrutinib (MESH:C000723100)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12536338/full.md

---
Source: https://tomesphere.com/paper/PMC12536338